Orlandi Ester, Giandini Tommaso, Iannacone Eva, De Ponti Elena, Carrara Mauro, Mongioj Valeria, Stucchi Claudio, Tana Silvia, Bossi Paolo, Licitra Lisa, Fallai Carlo, Pignoli Emanuele
Unit of Radiotherapy 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Unit of Medical Physics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Radiother Oncol. 2014 Nov;113(2):260-6. doi: 10.1016/j.radonc.2014.11.024. Epub 2014 Nov 29.
To compare volumetric modulated arc therapy (VMAT) and intensity modulated radiation therapy (IMRT) plans for treatment of unresectable paranasal sinuses cancers (PNSCs) with different clinical presentations.
Four patients treated for primary target volume only (group 1), four requiring elective nodal irradiation (group 2) and four with positive nodes in macroscopic disease (group 3) were selected. For each patient were generated 7 fields IMRT, coplanar VMAT (c-VMAT) and non-coplanar VMAT (nc-VMAT) treatment plans. Total doses were 70Gy and 54Gy to high dose planning target volume (HD-PTV) and low-dose-PTV, respectively. Dose-volume histogram, conformity and homogeneity index (CI and HI), and monitor units (MUs) per Gy were evaluated.
VMAT provided significantly better target coverage, in terms of V100% (Volume encompassed by the isodose 100%), than IMRT, in particular when nc-VMAT was used. In general, organ at risk sparing is similar with the three approaches, although nc-VMAT can allow a statistically significant reduction of dose to contralateral parotid gland and cochlea for all three groups.
VMAT can offer significant improvement of treatment for all unresectable PNSCs over existing IMRT techniques. In particular, nc-VMAT may be a further advantage for those patients with sinonasal cancers and involvement of the nodes in whom large volumes and complex/irregular shape have to be irradiated, even if clinical benefits should be established in the future.
比较容积调强弧形放疗(VMAT)和调强放疗(IMRT)计划对不同临床表现的不可切除鼻窦癌(PNSCs)的治疗效果。
选取仅治疗原发靶区的4例患者(第1组)、需要选择性淋巴结照射的4例患者(第2组)和肉眼可见病灶有阳性淋巴结的4例患者(第3组)。为每位患者生成7野IMRT、共面VMAT(c-VMAT)和非共面VMAT(nc-VMAT)治疗计划。高剂量计划靶区(HD-PTV)和低剂量计划靶区的总剂量分别为70Gy和54Gy。评估剂量体积直方图、适形度和均匀性指数(CI和HI)以及每Gy的监测单位(MUs)。
就V100%(等剂量线100%所包含的体积)而言,VMAT提供的靶区覆盖明显优于IMRT,尤其是使用nc-VMAT时。总体而言,三种方法对危及器官的保护相似,尽管nc-VMAT可使所有三组患者对侧腮腺和耳蜗的剂量在统计学上显著降低。
与现有的IMRT技术相比,VMAT可为所有不可切除的PNSCs提供显著更好的治疗效果。特别是,nc-VMAT对于那些鼻窦癌且有淋巴结受累、需要照射大体积且形状复杂/不规则区域的患者可能具有进一步的优势,即使未来仍需确定其临床获益。